Diabetes Mellitus (DM) is a very common condition with wide ranging and severe complications. DM leads to metabolic and vascular diseases including coronary artery disease (CAD), cerebrovascular disease, peripheral artery disease, eye disease and kidney disease. This can progress to heart attacks, strokes, amputations, dialysis and blindness. What is DM, how does it affect the vascular system and how do we treat it?
DM is common and the eighth leading cause of death in the United States (US). In 2021, 38 million Americans (16%) had diabetes and 38% of the US had prediabetes. Those numbers continue to rise. Patients with DM are five times more likely to develop heart disease then those who do not have DM.
DM is diagnosed by the following criteria: a hemoglobin A1c level > 6.5 % (hemoglobin A1c is a blood test that assesses the average blood sugar over the course of a month) or a fasting blood sugar level > 126 md/dl or any random blood sugar > 200 mg/dl. Prediabetes is a hemoglobin A1c between 5.7 and 6.4% or fasting blood sugar between 100 and 125 mg/dl.
The pathogenesis of DM is related to the actions of insulin, which is secreted by the pancreas and regulates the body’s blood sugar. Insulin lowers sugar (glucose) level in the blood and promotes increased uptake of sugar by the muscles for energy. There are two types of DM. Type 1 DM (5.7% of all DM) is caused by destruction of the cells used by the pancreas to make insulin. In Type 2 DM, the body is resistant to the effects of insulin. If insulin is impaired by either mechanism, the blood sugar goes up. Longstanding high levels of blood sugar leads to inflammation of the blood vessels and impaired function of the blood vessels. Two types of vascular complications ensue: microvascular and macrovascular. Microvascular complications include retinopathy (eye disease), neuropathy (nerve pain) and nephropathy (kidney damage). Macrovascular complications refer to inflammation and blockage in the heart, brain and peripheral arteries.
The goal of management of DM is to achieve a hemoglobin A1c under 7%. This can be done through diet, exercise and weight loss. Working with a dietician can help find foods that are low in sugar. Weight loss of 5 to 10% improves hemoglobin A1c and lowers cardiac risk. Other risk factors should be controlled as well. Blood pressure should be lowered to less than 130/80 mmHg. If there is concomitant kidney disease or protein in the urine, an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB) should be used as first line to delay the DM related progression of kidney disease. Cholesterol should be lowered with a statin with a goal of LDL (low density lipoprotein, the “bad” cholesterol) under 70 mg/dl. High triglycerides often accompany DM. If the triglyceride level is above 150 mg/dl, then high dose fish oil (icosapent ethyl) can reduce cardiac risk.
There are many medications available for control of blood sugar. Insulin injection is used to treat Type 1 DM. For Type 2 DM, especially for those with heart disease, three classes of medications are preferred. Treatment is usually begun with metformin. Metformin decreases glucose production by the liver, reduces the uptake of sugar in the gastrointestinal system and improves insulin sensitivity by increasing glucose uptake in the muscles. Metformin can help with weight loss and improve vascular function. Sodium glucose cotransporter-2 inhibitors (SGLT2) include Jardiance and Farxiga. These agents increase the excretion of glucose by the kidneys. SGLT2 agents have been shown to reduce cardiac events, cardiac mortality, heart failure hospitalizations and slow the progression of kidney disease. Glucagon-like peptide-1 receptor agonists (GLP1) also treat Type 2 DM and have similar beneficial effects on the heart as the SGLT2 agents, lowering major cardiac events. These agents also help with congestive heart failure and delay progression of disease in chronic kidney patients. Of course, GLP1 agonists are used to treat obesity, even in patients without DM. GLP1 agents include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). They act by having the pancreas release insulin only when the blood sugar is high, stopping secretion of glucagon (which tells the liver to release sugar into the blood), slowing the movement of food from the stomach (preventing spikes in blood sugar) and controlling hunger and food craving to help lose weight. GLP1 agents improve multiple risk factors for atherosclerosis including lowering weight, improving fat distribution (for example, decreasing waist circumference), lowering blood pressure, improving lipids and decreasing inflammation. Because of these factors, GLP1 agonists can lower the risk for major cardiac events by 20%.
Type 2 DM is preventable with lifestyle modifications. Effective lifestyle management includes watching calorie, carbohydrate and fat intake in the diet, maintaining a good body weight and exercising. In patients with obesity and high risk for DM, these lifestyle changes lowered the risk for DM by 34% over a ten-year period. If lifestyle isn’t working, the use of the GLP1 agonist semaglutide lowered the risk for DM by 73% in obese patients.
Life is full of sweet choices. One choice you should make is to try to avoid Type 2 DM and its myriad complications. So, choose to exercise regularly, watch your weight and keep the sweets to a minimum.




